Antibodies against CD5L for therapeutic and diagnostic uses

Description:

Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.

UTHealth Ref. No.: 2020-0016

Inventors: Dr. Zhiqiang An and Dr. Ningyan Zhang at UTHealth; Dr. Anil Sood at UT M.D. Anderson Cancer Center

Patent Status: PCT application PCT/US2021/025429 filed 4/1/2021; nationalized in US, CN, and EPO

License Available: world-wide, exclusive

Direct Link:

http://uthealth.technologypublisher.com/technology/54298

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.

Category(s):

Biologics

Oncology

Therapeutics

Bookmark this page

Download as PDF

For Information, Contact:

Christine Weaver

Director, Licensing and New Venture Development

University of Texas Health Science Center At Houston

Christine.Weaver@uth.tmc.edu

Inventors:

Zhiqiang An

Ningyan Zhang

Anil Sood